...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on

Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on

posted on Jun 05, 2020 07:03PM

CALGARY, Alberta, June 05, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the Company will host a Corporate Update Conference Call and Webcast on June 10th, 2020 at 9 am MT/11 am ET. The Company also announces its participation at the 57th ERA-EDTA Virtual Congress on June 9, 2020 with further details outlined below.

Conference Call & Webcast Details

For those wishing to join the June 10th Corporate Update Conference Call and Webcast, the event will start promptly at 9 am MT/11 am ET. It is highly recommended to access the webcast over the Internet using the following LINK. A replay of the webcast (using the same LINK provided) will be available for one month following the conclusion of the event.

If dialing in by phone, dial 1-800-319-4610 (within Canada / USA) or +1-604-638-5340 (International Toll). Callers should dial-in at least 10 min prior to the scheduled start time. A teleconference replay will be available for one month following the conclusion of the event and can be accessed by dialing 1-800-319-6413 (within Canada / USA) or +1-604-638-9010 (International Toll) and using the replay access code: 4697#.

57th ERA-EDTA Virtual Congress

Resverlogix is also pleased to announce that on June 9, 2020, Dr. Kam Kalantar-Zadeh, MD, MPH, PhD, Professor and Chief, Division of Nephrology, Hypertension, and Kidney Transplantation, University of California Irvine, Orange, California, USA, will give a virtual oral presentation at the 57th ERA-EDTA Virtual Congress, titled: “Effects of the bet-inhibitor apabetalone on cardiovascular events in patients with type 2 diabetes mellitus and acute coronary syndrome, according to presence or absence of chronic kidney disease. A BETonMACE trial report.” The presentation will be available via the Company website HERE, once available.

Share
New Message
Please login to post a reply